Cybin to Buy Clinical Trial From Entheon Biomedical to Advance Development of CYB004

09:58 AM EDT, 06/07/2022 (MT Newswires) -- Cybin (CYBN) said Tuesday it has agreed to buy a phase 1 study from Entheon Biomedical for $1 million Canadian dollars ($794,450) to boost the clinical devel

MT NewswiresJun 7, 2022 10:01 ET

BRIEF-Cybin Acquires Dmt Clinical Study From Entheon Biomedical

June 7 (Reuters) - Cybin Inc CYBN.NLB :* CYBIN ACQUIRES DMT CLINICAL STUDY FROM ENTHEON BIOMEDICAL* CYBIN INC- PURCHASE PRICE OF ACQUISITION IS $1,000,000 (CAD)Source text for Eikon: ID:nBw20D4Bma

reutersJun 7, 2022 09:05 ET

Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M

Cybin Acquires DMT Clinical Study From Entheon Biomedical For C$1M

Benzinga Real-time NewsJun 7, 2022 08:10 ET

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000. Each

Benzinga Real-time NewsApr 5, 2022 15:46 ET

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel, New Clinical Research Platform

01:46 PM EDT, 03/29/2022 (MT Newswires) -- Entheon Biomedical Corp. (ENBI.CSE), a biomedical company focused on the research and development of psychedelic drugs and biomarkers to provide personalized

MT NewswiresMar 29, 2022 13:51 ET

Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders

Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders. In the study — which is being

Seeking AlphaMar 15, 2022 11:06 ET